(Albany, USA) DelveInsight’s, “Advanced Urothelial Carcinoma Pipeline Insight 2025” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Advanced Urothelial Carcinoma pipeline landscape. It covers the Advanced Urothelial Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Advanced Urothelial Carcinoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in the Advanced Urothelial Carcinoma Pipeline. Dive into DelveInsight's comprehensive report today! @ Advanced Urothelial Carcinoma Pipeline Outlook
Key Takeaways from the Advanced Urothelial Carcinoma Pipeline Report
- In June 2025, Astellas Pharma Inc announced results of an Open-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab Versus Chemotherapy Alone in Previously Untreated Locally Advanced or Metastatic Urothelial Cancer
- In May 2025, Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the poster presentation of two abstracts at the 2025 American Society for Clinical Oncology (ASCO) Annual Meeting, taking place May 30-June 3 in Chicago.
- In April 2025, Janssen Research & Development LLC conducted a study is to: (a) characterize the safety and tolerability of and to identify the recommended Phase 2 dose (RP2D) and schedule for erdafitinib in combination with cetrelimab, and for erdafitinib in combination with cetrelimab and platinum (cisplatin and carboplatin) chemotherapy and; (b) to evaluate the safety and clinical activity of erdafitinib alone and in combination with cetrelimab in cisplatin-ineligible participants with metastatic or locally advanced urothelial cancer (UC) with select fibroblast growth factor receptor (FGFR) gene alterations and no prior systemic therapy for metastatic disease.
- DelveInsight’s Advanced Urothelial Carcinoma pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for Advanced Urothelial Carcinoma treatment.
- The leading Advanced Urothelial Carcinoma Companies such as Merck Sharp & Dohme LLC, Evopoint Biosciences Inc., Exelixis, Tyra Biosciences, Inc., BeiGene, BicycleTx Limited, Bristol-Myers Squibb, Sichuan Baili Pharmaceutical Co., Ltd., Nektar Therapeutics, Bayer, Abbisko Therapeutics Co., Ltd., Aurigene Discovery Technologies Limited, Adlai Nortye Biopharma Co., Ltd., Mabwell (Shanghai) Bioscience Co., Ltd. and others.
- Promising Advanced Urothelial Carcinoma Pipeline Therapies such as SHR-A2102, Adebrelimab injection, Selinexor, Pembrolizumab, 9MW2821, Toripalimab and others.
Stay ahead with the most recent pipeline outlook for Advanced Urothelial Carcinoma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Advanced Urothelial Carcinoma Treatment Drugs
Advanced Urothelial Carcinoma Overview:
Advanced Urothelial Carcinoma represents a late-stage malignancy originating from the urothelial lining of the bladder, ureters, or renal pelvis. Advanced Urothelial Carcinoma is primarily diagnosed in older adults, often linked to risk factors such as smoking, occupational exposure to carcinogens, and chronic bladder inflammation. Advanced Urothelial Carcinoma is commonly detected at a stage where tumors have invaded the muscle layer or metastasized to distant organs, complicating treatment outcomes. Advanced Urothelial Carcinoma management typically involves systemic chemotherapy, with cisplatin-based regimens serving as the standard first-line therapy. Advanced Urothelial Carcinoma patients who are cisplatin-ineligible may receive alternative agents like carboplatin or immunotherapy. Advanced Urothelial Carcinoma treatment has evolved significantly with the advent of immune checkpoint inhibitors targeting PD-1/PD-L1 pathways, improving survival rates in select patients. Advanced Urothelial Carcinoma therapeutic landscape also includes targeted therapies such as FGFR inhibitors for tumors with specific genetic alterations. Advanced Urothelial Carcinoma prognosis remains guarded, with five-year survival rates considerably lower than in localized disease. Advanced Urothelial Carcinoma ongoing research focuses on novel biomarkers and combination strategies to enhance treatment response. Advanced Urothelial Carcinoma highlights the importance of early detection and personalized medicine approaches to optimize patient outcomes and quality of life.
Advanced Urothelial Carcinoma Emerging Drugs Profile
- 9MW2821: Mabwell (Shanghai) Bioscience Co., Ltd.
9MW2821 is a novel Nectin-4 targeting ADC developed by ADC platform and automated high-throughput antibody discovery platform of Mabwell. It boasts the advantages of homogenous structure, high purity and being easy production. It has also demonstrated favorable druggability properties in binding affinity, endocytosis, preliminary in vivo and in vitro pharmacodynamic activities, drug metabolism properties and preliminary safety. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Advanced Urothelial Carcinoma.
- AZD4547: Abbisko Therapeutics Co, Ltd
AZD-4547 is an orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) with potential antineoplastic activity. FGFR inhibitor AZD4547 binds to and inhibits FGFR, which may result in the inhibition of FGFR-related signal transduction pathways, and, so, the inhibition of tumor cell proliferation and tumor cell death. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Advanced Urothelial Carcinoma.
- AUR106: Aurigene Discovery Technologies Limited
AUR106 is an orally bioavailable small molecule inhibitor of the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT) and the immunosuppressive ligand programmed cell death-1 ligand 1, with potential immune checkpoint inhibitory and antineoplastic activities. Upon oral administration, TIGIT/PD-L1 inhibitor AUR-106 simultaneously targets, binds to and inhibits TIGIT and PD-L1, thereby inhibiting their downstream signaling pathways. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Advanced Urothelial Carcinoma.
The Advanced Urothelial Carcinoma Pipeline Report Provides Insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Advanced Urothelial Carcinoma with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Advanced Urothelial Carcinoma Treatment.
- Advanced Urothelial Carcinoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Advanced Urothelial Carcinoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Advanced Urothelial Carcinoma market
Explore groundbreaking therapies and clinical trials in the Advanced Urothelial Carcinoma Pipeline. Access DelveInsight's detailed report now! @ New Advanced Urothelial Carcinoma Drugs
Advanced Urothelial Carcinoma Companies
Merck Sharp & Dohme LLC, Evopoint Biosciences Inc., Exelixis, Tyra Biosciences, Inc., BeiGene, BicycleTx Limited, Bristol-Myers Squibb, Sichuan Baili Pharmaceutical Co., Ltd., Nektar Therapeutics, Bayer, Abbisko Therapeutics Co., Ltd., Aurigene Discovery Technologies Limited, Adlai Nortye Biopharma Co., Ltd., Mabwell (Shanghai) Bioscience Co., Ltd. and others.
Advanced Urothelial Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
Advanced Urothelial Carcinoma Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
Unveil the future of Advanced Urothelial Carcinoma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Advanced Urothelial Carcinoma Market Drivers and Barriers
Scope of the Advanced Urothelial Carcinoma Pipeline Report
- Coverage- Global
- Advanced Urothelial Carcinoma Companies- Merck Sharp & Dohme LLC, Evopoint Biosciences Inc., Exelixis, Tyra Biosciences, Inc., BeiGene, BicycleTx Limited, Bristol-Myers Squibb, Sichuan Baili Pharmaceutical Co., Ltd., Nektar Therapeutics, Bayer, Abbisko Therapeutics Co., Ltd., Aurigene Discovery Technologies Limited, Adlai Nortye Biopharma Co., Ltd., Mabwell (Shanghai) Bioscience Co., Ltd. and others.
- Advanced Urothelial Carcinoma Pipeline Therapies- SHR-A2102, Adebrelimab injection, Selinexor, Pembrolizumab, 9MW2821, Toripalimab and others.
- Advanced Urothelial Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Advanced Urothelial Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Advanced Urothelial Carcinoma Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Advanced Urothelial Carcinoma Clinical Trials and FDA Approvals
Table of Content
- Introduction
- Executive Summary
- Advanced Urothelial Carcinoma: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Advanced Urothelial Carcinoma – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- 9MW2821: Mabwell (Shanghai) Bioscience Co., Ltd.
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- AZD4547: Abbisko Therapeutics Co, Ltd
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- AUR106: Aurigene Discovery Technologies Limited
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug name: Company name
- Drug profiles in the detailed report…..
- Inactive Products
- Advanced Urothelial Carcinoma Key Companies
- Advanced Urothelial Carcinoma Key Products
- Advanced Urothelial Carcinoma- Unmet Needs
- Advanced Urothelial Carcinoma- Market Drivers and Barriers
- Advanced Urothelial Carcinoma- Future Perspectives and Conclusion
- Advanced Urothelial Carcinoma Analyst Views
- Advanced Urothelial Carcinoma Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting
